Soluble or membrane-anchored ligands of NKG2D and their receptor have a critical role in the elimination of tumor cells and disease progression. Plasma samples of 98 patients with B-cell chronic lymphocytic leukemia (CLL) were analyzed with specific ELISA systems for soluble major histocompatibility complex class I-related chains (sMICA and sMICB) and UL-16-binding proteins (ULBP1, 2, and 3). The flow cytometric analysis of MICA on CLL cells and natural killer group 2 member D (NKG2D) receptors on NK cells was performed after thawing of frozen peripheral blood lymphocytes of CLL patients (N ¼ 51). Levels of sMICA, sMICB, and sULBP2 were significantly increased (Po0.001) compared with 48 controls, whereas sULBP1 3 were not detectable in patients and controls. Levels of sMICA4990 pg/ml (P ¼ 0.014), sMICB4200 pg/ml (P ¼ 0.0001), and sULBP24105 pg/ml (Po0.0001) were associated with poor treatment-free survival (TFS). Neither MICA nor NKG2D expression could be related to clinical parameters. In multivariate analysis Binet stage (P ¼ 0.002), sULBP2 (P ¼ 0.002) and ZAP-70 (P ¼ 0.002) were independent predictive factors for TFS. In patients with Binet stage A, sULBP2 levels4105 pg/ml were strongly associated (P ¼ 0.0025) with poor TFS. Our data show that soluble but not membrane-anchored NKG2D ligands or receptors are of prognostic significance in CLL. Moreover, sULBP2 seems to be useful to identify early-stage patients with risk of disease progression.
Introduction
The natural killer (NK) group 2 member D (NKG2D) receptor is a type II transmembrane-anchored glycoprotein. It is expressed as a disulfide-linked homodimer on NK cells, g/d T cells, and cytotoxic CD8 a/b T cells. 1 The engagement of NKG2D with its surface-expressed ligands results in the induction of cytotoxicity by resting or activated NK cells and it provides costimulatory signals to T cells, enhancing their cytolytic activity, and cytokine production. 2, 3 Known ligands of the NKG2D immune receptor are the major histocompatibility complex class I-related chains (MIC) A and B and the UL-16-binding proteins (ULBP1, ULBP2, ULBP3, ULBP3, ULBP4, RAET1G, and RAET1L). Under physiological conditions the expression of MICA is restricted to gastrointestinal epithelium, endothelial cells, and fibroblasts. 4 ,5 NKG2DL, however, are stress-inducible and often found to be expressed on a variety of solid tumors and lymphoproliferative malignancies. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Consequently, the expression of both, the NKG2D receptor and its ligands, has a crucial role in immune defense mechanisms against tumor cells by T and NK cells: studies in mice showed that NK and CD8 T cells eliminated NKG2DL-positive tumor cells through the NKG2D receptor. 16, 17 It was further shown that NKG2D protected the host from tumor initiation. 18 Therefore, NKG2D/NKG2DL might represent target molecules for the development of novel therapeutic strategies to mount tumor immunity in vivo. 19 The release of NKG2DL from the cell surface of tumor cells counteracts the immunological surveillance by T and NK cells in many ways: (i) the reduction of NKG2DL expression prevents the recognition and elimination of tumor cells by T and NK cells; (ii) soluble NKG2DL (sNKG2DL) molecules impair the effector function of T and NK cells by the systemic downregulating of NKG2D surface expression; [20] [21] [22] and (iii) sNKG2DL causes the expansion of the strong immune suppressive CD4 þ NKG2D þ T cells. 23 Released NKG2DL can be found in supernatants of NKG2DL-positive tumor cell lines and in sera of tumor patients with different malignancies. Elevated levels of sNKG2DL are correlated with metastasis, advanced disease stage, and poor prognosis. 12, [20] [21] [22] [24] [25] [26] [27] [28] Soluble MICA (sMICA) is reported to be an independent prognostic factor for the overall and progression-free survival in multiple myeloma (MM) patients. Elevated sMICA levels seem to be associated with an enhanced risk of disease progression in MM patients with disease stage I. 29 Thus, the NKG2D/NKG2DL system fulfills all criteria of an ideal prognostic parameter: (i) it is relevant in the immune biology of tumors; (ii) it represents target molecules for new therapeutic approaches; and (iii) it can be used to identify patients with high risk of early disease progression.
In chronic lymphocytic leukemia (CLL) patients the individual courses of disease are highly heterogeneous: Many CLL patients are asymptomatic and live for decades with their disease without any treatment requirements, whereas others experience an aggressive form of disease leading to premature death. Therefore, diagnostic markers predicting the clinical progression in CLL patients are of great importance for the clinical management of CLL patients. A number of prognostic markers, including the ZAP-70, CD38, immunoglobulin heavy chain variable gene (IGHV) mutation status, and cytogenetic abnormalities, are described to be helpful for the prediction of survival and treatment requirements of early-stage CLL patients. [30] [31] [32] [33] [34] Although most prognostic parameters mentioned above are linked to leukemic cell biology, they cannot be used as direct target molecules for immune therapies. In our study, we analyzed the prognostic relevance of the NKG2D receptor and its ligands in 98 CLL patients. The results revealed that among sNKG2DL, sULBP2 is a potent prognostic marker for the identification of early-stage CLL patients with risk of disease progression.
Materials and methods

Patients
In total, 98 CLL patients were enrolled between June 2002 and September 2007 into this retrospective study. The patients were analyzed for biological and clinical characteristics including age, sex, Binet stage, treatment history, time from diagnosis to first treatment, hemoglobin concentration, serum activities of lactate dehydrogenase and thymidine kinase, as well as serum concentrations of b2-microglobulin (b2m). In each patient, morphologic diagnosis of CLL was confirmed by flow cytometry revealing a typical CD19
Expression of ZAP-70 (N ¼ 71, cutoff 20%) and CD38 (N ¼ 96, cutoff 30%) was determined by flow cytometry as described. 31 FISH analysis was performed as described earlier. 35 Treatment history was available for all patients. Chemotherapy was initiated according to the guidelines of treatment for CLL. 36 
Blood specimens
Ethylenediaminetetraacetate plasma samples were procured from the patients with informed consent according to the institutional guidelines during routine follow-up visits. Ethylenediaminetetraacetate plasma samples were centrifuged at 1.500 g for 10 min and the supernatants were stored at À30 1C until usage. Samples from patients with treatment history were collected at least 6 months after therapy. To obtain normal ranges for sMICA and sMICB as well as sULBP1, sULBP2, sULBP3, and Ethylenediaminetetraacetate plasma samples from 48 age-matched healthy blood donors (61.5 ± 1.3 years) were additionally collected and tested.
Peripheral blood lymphocytes from 51 CLL patients (age at diagnosis: 60.2 ± 1.1 year) and 19 healthy age-matched controls (64.1 ± 2.2 years) were isolated from heparinized blood samples by Lymphoprep (Invitrogen, Karlsruhe, Germany) density gradient centrifugation and cryopreserved until further analysis.
Determination of sMICA/B and sULBP1-3 by ELISA Determination of the sMICA levels were performed as described earlier with following modifications: for capturing of sMICA molecules the mAb AMOI (BAMOMAB, Munich, Germany) was used at a final concentration of 25 ng/ml. The detection of bound sMICA molecules was performed by the biotin-coupled polyclonal goat anti-human MICA (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany) diluted to 400 ng/ml in phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin and 2% inactivated goat serum. Bound detection antibodies were recognized by streptavidin conjugated with horseradish peroxidase (R&D Systems GmbH) being diluted 1-200 in PBS with 1% bovine serum albumin; 3,3 0 ,5,5 0 -tetramethybenzidine (Sigma-Aldrich Chemie GmbH, Munich, Germany) served as substrate solution. Absorbance was measured at 450 nm (Biotek Instruments, Winooski, VT, USA). For the determination of sMICB, ULBP1, 2, and 3 levels commercial ELISA kits (R&D Systems GmbH) were performed according to the protocols of the manufacturer except one modification: For the sULBP2 ELISA format the monoclonal antibody BUM01 (BAMOMAB GmbH) was used as capture reagent instead of the provided antibody of the respective kit to improve the detection limit.
Recombinant MICA, MICB, ULBP1, ULBP2, or ULBP3 protein fused with Fc portion of human IgG (R&D Systems GmbH) were used as standard reagents. Determination of sNKG2D ligand plasma levels was performed by four-parameter curve fitting. The detection limit of sMICA or MICB ELISA was 20.4 and 31.0 pg/ml. The ULBP1, 2, and 3 ELISA formats revealed a detection limit of 93.4, 14.5, and 173.1 pg/ml, respectively. The detection limits were calculated according the DIN 32645. For sMICA, sMICB, and sULBP2 the interaassay coefficients of variations were 4.1, 3.7, and 4.0%, respectively, whereas the interassay coefficients of variations were 14.3% for sMICA, 9.8% for sMICB, and 10.6% for sULBP2.
Flow cytometric analysis of MICA and NKG2D
After the careful thawing of frozen peripheral blood lymphocytes in fetal calf serum, the cells were washed with PBS (pH 7.4) and blocked with 20% human serum in PBS for 1 h at 4 1C. MICA expression on CLL cells was evaluated by dual-color immunofluorescence staining. To this end, peripheral blood lymphocytes were incubated for 15 min with 15 ml of the MICAspecific monoclonal antibody AMOI (IgG1, BAMOMAB GmbH) followed by phycoerythrin-conjugated goat anti-mouse IgG. After washing, the B cells of the CLL patients were detected by using 20 ml of PerCP-conjugated anti-human CD19 (Becton Dickinson, San Jose, CA, USA). Expression of the NKG2D receptor on NK was analyzed by using APC-conjugated antihuman CD56 (Becton Dickinson) in combination with phycoerythrin-conjugated anti-human NKG2D (Becton Dickinson) and FITC-conjugated anti-human CD3 (Becton Dickinson). Isotypematched APC, FITC, PerCP-and phycoerythrin-labeled mouse IgG served as negative controls. FACS Calibur (Becton Dickinson) was used for flow cytometric analysis of the respective surface molecule. Data were acquired and evaluated by CellQuest software (Becton Dickinson).
Statistical analysis
Data are given in pg/ml and presented as mean±standard error of the mean (s.e.m.). After testing for Gaussian distribution, continuous variables were compared with clinical or laboratory parameters by non-parametric Mann-Whitney test, Student's t-test, or Dunn's multiple comparison test. Spearman correlation analysis was used to correlate the sNKG2DL values to laboratory parameters. For categorical data, the w 2 -test was used. Probabilities of the patients' treatment-free survival (TFS) or overall survival (OS) were analyzed by the Kaplan-Meier method combined with log-rank test. The starting point of the calculations was the date of diagnosis. The primary endpoints were OS and time to first treatment. OS was measured from date of diagnosis until death because of CLL. OS times of patients who died because of other reasons or who were alive at the last follow-up were censored. The cutoff values for sMICA/B and sULBP2 were determined regarding optimal values of sensitivity and specificity for the prediction of TFS of CLL patients using Stoller's univariate non-parametric determination analysis and the receiver operating characteristic (ROC) curve analysis. Multivariate analysis was performed by Cox regression analysis. Differences with a P-value o 0.05 were considered statistically significant. All calculations were performed using either SPSS 15.0 software (SPSS Inc., Chicago, IL, USA) or BIAS version 8.6 (Epsilon Verlag, Frankfurt, Germany) or GraphPad Prism 3.0 (GraphPad Software, San Diego, CA, USA).
Results
Elevated sMICA, sMICB, and sULBP2 plasma levels in CLL patients
Ethylenediaminetetraacetate plasma samples from 98 CLL patients with a median age of 61 years at diagnosis were analyzed for sMICA, sMICB, and sULBP1, 2, and 3. The sMICA, sMICB, and sULBP2 levels of CLL patients were approximately threefold higher (Po0.0001) than in 48 healthy controls (sMICA: 859 ± 68 vs 305 ± 39; sMICB: 182 ± 17 vs 55 ± 10; sULBP2: 141±11 vs 41±6; Figure 1 ). Neither sULBP1 nor sULBP3 levels were detectable in the plasma samples of patient nor of controls. sMICB (P ¼ 0.001) and sULBP2 (P ¼ 0.009) were significantly increased in patients with advanced disease stage. The sMICA, sMICB, and sULBP2 levels of CLL patients did not differ with regard to age (o 60 vs 460 years), gender, the prognostically relevant cytogenetic aberrations in chromosomes 11, 12, 13, 17, as well as to the CD38 þ , ZAP-70 þ , and IGHV status (Table 1) .
MICA and NKG2D surface expression in CLL patients
In addition to sNKG2DL molecules, the surface expression of MICA on CLL cells (Figure 2a ) and of NKG2D receptor on NK cells (Figure 2b ) was studied in 51 CLL patients. MICA expressions on CLL cells were significantly (P ¼ 0.031) increased in CLL patients compared with healthy age-matched controls: In patients the relative mean fluorescence intensity (MFI) of MICA on CLL cells was 1.75 ± 0.08 whereas in controls the relative MFI on B cells was 1.45±0.07 ( Figure 2 Correlation of sMICA, sMICB, and sULBP2 with laboratory parameters in CLL patients
As shown in Table 2 , serum levels of b2 m (N ¼ 88) as well as serum activities of lactate dehydrogenase (N ¼ 94) and thymidine kinase (N ¼ 72) were positively correlated to the sNKG2DL sMICA, sMICB, sULBP2 with correlation coefficients (r) ranging from 0.219 to 0.337. Of note, levels of sMICA and sULBP2 were negatively correlated with relative numbers of peripheral blood NK cells (Table 2) . No correlation was observed between hemoglobin, absolute, or relative lymphocyte numbers and sMICA, sMICB, or sULBP2. In addition, there was no correlation between the expression of MICA on CLL cells, or of NKG2D on NK cells with the current levels of serum parameters such as b2 m, hemoglobin, serum activities of lactate dehydrogenase, and thymidine kinase and sNKGDL (data not shown).
The prognostic significance of sMICA, sMICB, and sULBP2 levels in CLL patients
As shown in Table 1 , levels of sMICB and sULBP2, but not of sMICA, were significantly higher in patients with early treatment requirement compared with patients without treatment history (sMICA: 1005±109 vs 741±84, P40.05; sMICB: 268±38 vs 113 ± 15, Po0.001; sULBP2: 198 ± 18 vs 96 ± 12, Po0.001).
To analyze the prognostic significance for the TFS, sMICA, sMICB, and sULBP2 levels were subjected to non-parametric determination analysis and ROC analysis (Figure 3) . With regard to the predictive value of TFS, an optimal cutoff value of 990 pg/ml was defined for sMICA (sensitivity: 72.2%; specificity: 56.8%).
The cutoff values of sMICB and sULBP2 were 200 pg/ml (sensitivity: 83.3%; specificity: 60.4%) and 105 pg/ml (sensitivity: 81.8%; specificity: 68.5%), respectively. No statistically relevant cutoff values could be defined for the MICA expression on leukemic cells and NKG2D receptor on NK cells (data not shown).
Using above mentioned cutoff levels, the Kaplan-Meier plot combined with log-rank test (Figure 4a -c) revealed significant probabilities of improved TFS for CLL patients with levels of sMICA o990 pg/ml (P ¼ 0.0135, N ¼ 40), sMICB o200 pg/ml (Po0.0001; N ¼ 36), and sULBP2 o105 pg/ml (P ¼ 0.0001; N ¼ 53). For patients having sMICA, sMICB, and sULBP2 levels below the respective cutoff values, the mean time intervals from diagnosis to initiation of chemotherapy were 211 ± 25 s.e.m., 226±25 s.e.m., and 248±30 s.e.m. months, respectively. In patients with levels above the cutoff values the TFS was clearly reduced (sMICA: 72±10 s.e.m. months, N ¼ 40; sMICB: 59±9 s.e.m. months, N ¼ 36; sULBP2: 73 ± 11 s.e.m. months, N ¼ 53).
For sULBP2 (Table1; Figure 4d ) but not for sMICA or sMICB (data not shown) we could show a significant (P ¼ 0.033) difference in OS: mean OS was significant reduced for patients with sULBP2 levels 4105 pg/ml compared with those patients with levels below this cutoff value. These analyses, however, are based on only eight events.
sULBP2, but not sMICA or sMICB, is an independent prognostic factor for TFS Besides sMICA, sMICB, and sULBP2, the Binet stage at the time point of diagnosis (A vs B/C), age at diagnosis (p60 years vs 460 years), gender and the established prognostic markers ZAP-70 (o20% vs X20%), CD38 (o30% vs X30%), and IGHV To analyze the predictive value of sULBP2 levels for the prognosis of CLL patients in Binet stage A, all patients in stages B and C (N ¼ 30) were excluded from data analysis using the Kaplan-Meier method combined with log-rank test. The analysis of 68 CLL patients in Binet stage A revealed that sULBP2 levels 4105 pg/ml were strongly associated with an enhanced risk for early treatment requirement after diagnosis ( Figure 5 ). For these patients (N ¼ 34) the mean TFS was significantly reduced with 
Discussion
The NKG2D/NKG2DL system is involved in both the innate and the adaptive immune response, and thereby has an important function in the immune surveillance of cancer cells. So far, the Abbreviations: b2m, b2-microglobulin; CLL, chronic lymphocytic leukemia; Hb, hemoglobin; LDH, lactate dehydrogenase; N, number of patients; NK, natural killer; NKG2D, natural killer group 2 member D; n.s., not significant; P, significance; r, correlation coefficient; sMICA/B, soluble major histocompatibility complex class I-related chains; TK, thymidine kinase; ULBP, UL-16-binding protein.
Spearman correlation analysis was used to relate the sNKG2DL values to serum markers. Soluble NKG2D ligands in chronic lymphocytic leukemia H Nückel et al functional role and/or prognostic significance of this receptor/ ligand system was investigated in various hematological diseases, such as myelodysplastic syndrome, 10 acute lymphoblastic leukemia, 37 acute myeloid leukemia, 8, 38 chronic myelogenous leukemia, 6 and MM 7,19,29 but not in CLL. Therefore, we investigated in this study the expression of sNKG2DL (sMICA, sMICB, sULBP1, sULBP2, sULBP3), the surface expression of MICA on CLL cells, and its receptor expression on NK cells in CLL patients. The most important results of our study are (i) the sNKG2DL sMICA, sMICB, and sULBP2, but not sULBP1 or sULBP3, are significantly increased in CLL patients compared with healthy controls; (ii) the TFS were significantly prolonged for patients with levels of sMICA o990 pg/ml, sMICB o200 pg/ml, and sULBP2 o105 pg/ml; (iii) sULBP2, but not the other sNKG2DL, represent an independent prognostic factor for TFS; (iv) analysis of sULBP2 levels allows the identification of CLL patients with risk of early tumor progression; and (v) contrary to sNKG2DL, the membrane-anchored MICA and the receptor expression are of no prognostic relevance in CLL.
It is of note that in patients and healthy controls the highest levels of sNKG2DL were obtained for sMICA followed by sMICB and sULBP2, whereas sULBP1 and 3 were not detectable. Nevertheless, it cannot be ruled out that the detection lack of sULBP1 and 3 molecules might be attributed to the low sensitivity of ELISA formats used.
Both the increased levels of sMICA/B and sULBP2 in CLL patients and the further enhanced levels in advance disease stage suggest that these molecules originated from tumor cells. Indeed, NKG2DL are broadly expressed on hematopoietic malignancies and it is very likely that the presence of such high amounts in blood is a result of tumor cell turnover. This is supported by the fact that levels of sMICA/B and sULBP2 are found to be correlated to levels of tumor cell turnover indicators such as b2m and lactate dehydrogenase. On the other hand, sNKG2DL are not correlated to the absolute and relative number of lymphocytes. Therefore, it is tempting to speculate that certain CLL cells exhibit an intrinsic property being responsible for the release of NKG2DL. Pilot studies showed that isolated CLL cells from four patients or isolated B cells of healthy donors (N ¼ 3) did not release sNKG2DL without any stimulus (data not shown). Thus, the conditions under which sNKG2DL are released by CLL or B cells remain to be investigated in future studies.
Interestingly, MICA and ULBP are often co-expressed by carcinoma cell lines, whereas the MICA(À) ULBP(þ) phenotype has been detected in T-cell leukemia cell lines and the MICA(À) ULBP(À) phenotype is described for acute myeloid leukemia.
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Especially for MICA and ULBP2 molecules it could be shown that considerable amounts are shed from tumor cells by the action of disulfide isomerase, ERp5 and metalloproteases. [39] [40] [41] Thus, cell turnover and shedding have to be taken into consideration as mechanisms for the release of NKG2DL molecules.
So far, only sMICA and/or sMICB have been reported to be correlated to cancer stage and metastasis. 22, 24, 29 For MM, sMICA is described as an independent prognostic marker for OS and progression-free survival. 22, 24, 29 This study clearly shows Soluble NKG2D ligands in chronic lymphocytic leukemia H Nückel et al that sULBP2 rather than sMICA or sMICB is of prognostic relevance for disease progression and OS of CLL patient. Moreover, we were able to identify sULBP2 but not sMICA or sMICB as a new independent prognostic marker for disease progression. As only 8 out of the 98 CLL patients died during our observation interval we could not establish any of the sNKG2DL as well as any of the other established markers as an independent prognostic factor for the OS (data not shown).
Our results are in line with a recent study analyzing levels of sNKG2DL in patients with malignant melanoma. As in our study, sULBP2 was associated as an indicator of poor prognosis superior to sMICA. 42 The functional consequences of increased sULBP2, however, remain speculative. It is reported that tumor-derived sMIC ligands impair the NKG2D receptor expression on T and NK cells. 21 The strong association of sULBP2 with clinical outcome of CLL patients supports the idea that sULBP2 contributes to the immune evasion of tumor cells as already suggested for MICA and MICB. As for malignant melanoma patients 42 we were not able to find either an impaired NKG2D expression on NK cells in CLL patients compared with age-matched healthy controls or a correlation of sNKG2DL levels with the receptor surface expression on NK cells. However, we did find a negative correlation of sMICA and sULBP2 with the relative number of peripheral blood NK cells in CLL patients as already described for MM. 29 The low number of NK cells in CLL patients is in agreement with a recent study suggesting NK and T-cell count as prognostic factors for the prediction of TFS. 43 Further studies will have to validate whether other mechanisms than sMIC-induced endocytosis or degradation of NKG2D are operative as immune escape mechanisms. In this context it is of note that the transforming-growth-factor-b-1, which is expressed together with NKG2DL on tumor-derived exosomes, is preferentially responsible for downmodulation of NKG2D expression. In contrast to this, sNKG2DL-positive exosomes derived from cultured peripheral blood lymphocytes of healthy donors did not co-express transforming-growth-factor-b-1 and consequently did not modulate the corresponding effector function. 44 On the basis of the negative correlation between sNKG2DL levels and relative NK cell numbers we would speculate that sNKG2DL molecules co-expressing apoptosis-mediating molecules on exosomes may be responsible for the low NK and T-cell count in CLL patients. Such an apoptosis-inducing mechanism has already been described for tumor-derived exosomes coexpressing HLA-I and FasL. 45 Further investigation will have to clarify the functional consequences of the sNKG2DL release for the respective effector cells in CLL patients.
Owing to limited cell material we analyzed only the MICA expression on CLL, but not the one of MICB or ULBP2. Therefore, our study unfortunately misses important information about the expression of these molecules on CLL cells. Nevertheless, we could exclude the prognostic relevance of MICA expression on CLL cells. Although an increased MICA expression is observed in various human malignancies, to date there are no clinical data directly supporting the concept that elevated NKG2D ligand surface expression in fact leads to an enhanced tumor immunity as shown in mouse model. 17, 18 The association of increased ULBP2 expression on ovarian cancer cells with poor prognosis gives reason to challenge that concept. 46 In conclusion, our study shows that sNKG2DL molecules are of prognostic relevance in CLL. Among them sULBP2 could be established as an independent marker for tumor progression, which helps to identify CLL patients with early treatment requirement. Further studies will have to investigate whether NKG2DL/sNKG2DL can be used as new target molecules for therapeutic approaches in CLL.
